APPELHUS 3期开放标签研究设计:因子B抑制剂伊普可泮治疗非典型溶血性尿毒症综合征
APPELHUS(NCT04889430)是一项多中心、单臂、开放标签3期研究,评估口服因子B抑制剂伊普可泮在50例未接受过补体抑制剂治疗的原发性补体介导aHUS患者中的疗效与安全性。患者接受伊普可泮200 mg每日两次,主要终点为26周治疗期间不使用血浆置换/输注或抗C5抗体的情况下达到完全TMA缓解的比例。
要点
- 伊普可泮为口服近端补体替代途径抑制剂,特异性结合因子B。
- 研究纳入需有TMA证据且未接受过补体抑制剂(包括抗C5)治疗的aHUS患者。
- 主要终点为26周内不使用血浆置换/输注或抗C5抗体达到完全TMA缓解的比例。
核心结论
- APPELHUS研究将确定伊普可泮在aHUS患者中是否安全有效。
- 伊普可泮有潜力成为有效且安全、口服给药便利的aHUS治疗选择。
研究设计与样本
- 多中心、单臂、开放标签3期研究(APPELHUS;NCT04889430),计划纳入50例原发性补体介导aHUS且未接受过补体抑制剂治疗(包括抗C5)的患者。
- eligible患者需有TMA证据:血小板计数<150 × 10^9/L、乳酸脱氢酶≥1.5倍正常上限、血红蛋白≤正常下限、血清肌酐≥正常上限。
- 患者接受伊普可泮200 mg每日两次。
关键数值与推荐
- 主要目标为评估26周伊普可泮治疗期间不使用血浆置换或输注或抗C5抗体的情况下达到完全TMA缓解的患者比例。
- 入组TMA标准:血小板计数<150 × 10^9/L、乳酸脱氢酶≥1.5倍正常上限、血红蛋白≤正常下限、血清肌酐≥正常上限。
- 伊普可泮给药方案:200 mg每日两次。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening form of thrombotic microangiopathy (TMA) which is caused by dysregulation of the alternative complement pathway (AP). Complement inhibition is an effective therapeutic strategy in aHUS, though current therapies require intravenous administration and increase the risk of infection by encapsulated organisms, including meningococcal infection. Further studies are required to define the optimal duration of existing therapies, and to identify new agents that are convenient for long-term administration. Iptacopan (LNP023) is an oral, first-in-class, highly potent, proximal AP inhibitor that specifically binds factor B (FB). In phase 2 studies of IgA nephropathy, paroxysmal nocturnal hemoglobinuria, and C3 glomerulopathy, iptacopan inhibited the AP, showed clinically relevant benefits, and was well tolerated. Iptacopan thus has the potential to become an effective and safe treatment for aHUS, with the convenience of oral administration. METHODS: Alternative Pathway Phase III to Evaluate LNP023 in aHUS (APPELHUS; NCT04889430) is a multicenter, single-arm, open-label, phase 3 study to evaluate the efficacy and safety of iptacopan in patients (N = 50) with primary complement-mediated aHUS naïve to complement inhibitor therapy (including anti-C5). Eligible patients must have evidence of TMA (platelet count <150 × 109/l, lactate dehydrogenase ≥1.5 × upper limit of normal, hemoglobin ≤ lower limit of normal, serum creatinine ≥ upper limit of normal) and will receive iptacopan 200 mg twice daily. The primary objective is to assess the proportion of patients achieving complete TMA response without the use of plasma exchange or infusion or anti-C5 antibody during 26 weeks of iptacopan treatment. CONCLUSION: APPELHUS will determine if iptacopan is safe and efficacious in patients with aHUS.
引用
- Kavanagh D, Greenbaum LA, Bagga A, et al. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome. Kidney Int Rep. 2023. PMID: 37441479. doi:10.1016/j.ekir.2023.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。